Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/C1S_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C1S_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/C1S_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C1S_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/C1S_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C1S_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/C1S_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001097014 | Skin | cSCC | transport along microtubule | 58/4864 | 155/18723 | 1.09e-03 | 7.24e-03 | 58 |
GO:003410927 | Skin | cSCC | homotypic cell-cell adhesion | 37/4864 | 90/18723 | 1.22e-03 | 7.91e-03 | 37 |
GO:000808817 | Skin | cSCC | axo-dendritic transport | 32/4864 | 75/18723 | 1.22e-03 | 7.92e-03 | 32 |
GO:19057109 | Skin | cSCC | positive regulation of membrane permeability | 22/4864 | 48/18723 | 2.31e-03 | 1.35e-02 | 22 |
GO:00723847 | Skin | cSCC | organelle transport along microtubule | 34/4864 | 85/18723 | 3.22e-03 | 1.76e-02 | 34 |
GO:19021109 | Skin | cSCC | positive regulation of mitochondrial membrane permeability involved in apoptotic process | 18/4864 | 38/18723 | 3.64e-03 | 1.95e-02 | 18 |
GO:00324382 | Skin | cSCC | melanosome organization | 14/4864 | 28/18723 | 5.47e-03 | 2.73e-02 | 14 |
GO:19021087 | Skin | cSCC | regulation of mitochondrial membrane permeability involved in apoptotic process | 20/4864 | 45/18723 | 5.54e-03 | 2.74e-02 | 20 |
GO:00487532 | Skin | cSCC | pigment granule organization | 14/4864 | 29/18723 | 8.08e-03 | 3.74e-02 | 14 |
GO:00482782 | Skin | cSCC | vesicle docking | 24/4864 | 59/18723 | 9.59e-03 | 4.30e-02 | 24 |
GO:00330594 | Skin | cSCC | cellular pigmentation | 22/4864 | 53/18723 | 9.80e-03 | 4.33e-02 | 22 |
GO:00060916 | Stomach | GC | generation of precursor metabolites and energy | 88/1159 | 490/18723 | 6.82e-20 | 9.27e-17 | 88 |
GO:00090606 | Stomach | GC | aerobic respiration | 49/1159 | 189/18723 | 3.25e-18 | 3.54e-15 | 49 |
GO:00453336 | Stomach | GC | cellular respiration | 54/1159 | 230/18723 | 7.63e-18 | 6.91e-15 | 54 |
GO:00159806 | Stomach | GC | energy derivation by oxidation of organic compounds | 64/1159 | 318/18723 | 2.79e-17 | 2.16e-14 | 64 |
GO:000609111 | Stomach | CAG with IM | generation of precursor metabolites and energy | 86/1050 | 490/18723 | 1.45e-21 | 1.93e-18 | 86 |
GO:000906011 | Stomach | CAG with IM | aerobic respiration | 49/1050 | 189/18723 | 5.39e-20 | 5.75e-17 | 49 |
GO:004533311 | Stomach | CAG with IM | cellular respiration | 54/1050 | 230/18723 | 9.39e-20 | 8.34e-17 | 54 |
GO:001598011 | Stomach | CAG with IM | energy derivation by oxidation of organic compounds | 64/1050 | 318/18723 | 1.96e-19 | 1.49e-16 | 64 |
GO:000906021 | Stomach | CSG | aerobic respiration | 49/1034 | 189/18723 | 2.82e-20 | 3.12e-17 | 49 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517126 | Endometrium | AEH | Coronavirus disease - COVID-19 | 99/1197 | 232/8465 | 5.19e-27 | 3.37e-25 | 2.47e-25 | 99 |
hsa05171112 | Endometrium | AEH | Coronavirus disease - COVID-19 | 99/1197 | 232/8465 | 5.19e-27 | 3.37e-25 | 2.47e-25 | 99 |
hsa0517127 | Endometrium | EEC | Coronavirus disease - COVID-19 | 99/1237 | 232/8465 | 7.43e-26 | 4.89e-24 | 3.65e-24 | 99 |
hsa0517136 | Endometrium | EEC | Coronavirus disease - COVID-19 | 99/1237 | 232/8465 | 7.43e-26 | 4.89e-24 | 3.65e-24 | 99 |
hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa051339 | Esophagus | ESCC | Pertussis | 48/4205 | 76/8465 | 1.21e-02 | 2.77e-02 | 1.42e-02 | 48 |
hsa05171310 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
hsa0513314 | Esophagus | ESCC | Pertussis | 48/4205 | 76/8465 | 1.21e-02 | 2.77e-02 | 1.42e-02 | 48 |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa051332 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa051333 | Liver | HCC | Pertussis | 48/4020 | 76/8465 | 4.17e-03 | 1.27e-02 | 7.06e-03 | 48 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C1S | SNV | Missense_Mutation | | c.1204C>G | p.His402Asp | p.H402D | P09871 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
C1S | insertion | In_Frame_Ins | novel | c.387_388insCGCCGCACCACCAAAGAAGGTGCTTGTGTTTGTCAGACAAAT | p.Ala129_Thr130insArgArgThrThrLysGluGlyAlaCysValCysGlnThrAsn | p.A129_T130insRRTTKEGACVCQTN | P09871 | protein_coding | | | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
C1S | deletion | Frame_Shift_Del | novel | c.153delN | p.Leu52SerfsTer21 | p.L52Sfs*21 | P09871 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
C1S | SNV | Missense_Mutation | novel | c.1810N>G | p.Thr604Ala | p.T604A | P09871 | protein_coding | tolerated(0.61) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
C1S | SNV | Missense_Mutation | novel | c.1710N>T | p.Trp570Cys | p.W570C | P09871 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BI-A0VS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
C1S | SNV | Missense_Mutation | rs782226018 | c.362C>T | p.Thr121Met | p.T121M | P09871 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
C1S | SNV | Missense_Mutation | | c.527G>T | p.Ser176Ile | p.S176I | P09871 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-A6-2679-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C1S | SNV | Missense_Mutation | rs781887755 | c.1447C>T | p.Pro483Ser | p.P483S | P09871 | protein_coding | tolerated(0.15) | benign(0.18) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C1S | SNV | Missense_Mutation | novel | c.80N>C | p.Asn27Thr | p.N27T | P09871 | protein_coding | deleterious(0.01) | possibly_damaging(0.816) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
C1S | SNV | Missense_Mutation | rs781845594 | c.1327N>A | p.Asp443Asn | p.D443N | P09871 | protein_coding | tolerated(0.55) | benign(0.025) | TCGA-DM-A1D0-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | TNT009 | | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | inhibitor | 252166820 | | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | Cinryze | CINRYZE | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | TS01 | | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | ANX005 | | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | antibody | 354702279 | SUTIMLIMAB | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | SHP616 | | |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | MBL | | 10878362 |
716 | C1S | ENZYME, PROTEASE, DRUGGABLE GENOME | | ANTITHROMBIN | | |